Results 61 to 70 of about 89,766 (303)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

Frontiers in Immunology, 2022
Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients.
Jennifer R. Blase, David Frame, Thomas F. Michniacki, Kelly Walkovich   +3 more
doaj   +1 more source

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y., Al-Tawfiq, Jaffar A., Momattin, Hisham   +2 more
core   +1 more source

De Novo Design and Directed Evolution Refinement of Mirror‐Image Protein Binders Targeting Interleukin‐4

Advanced Science, EarlyView.
This study presents the de novo design and directed evolution of a mirror‐image D‐protein inhibitor targeting human interleukin‐4 (IL‐4). The engineered molecule exhibits nanomolar binding affinity for IL‐4 and effectively inhibits IL‐4–mediated signaling.
Liqing Xu, Yuxiang Ren, Tongyue Wang, Hongyong Li, Yue Yao, Lei Liu, Ke Sun, Peilong Lu   +7 more
wiley   +1 more source

Human Monoclonal Antibodies Neutralizing Human Cytomegalovirus

Journal of General Virology, 1987
Hybridomas producing human monoclonal antibodies (MAbs) against human cytomegalovirus (CMV) were generated by fusion of human spleen cells and mouse myeloma cells. Two of the six MAbs obtained neutralized viral infectivity even at concentrations lower than 1 microgram/ml. One MAb required complement for neutralization but the other did not.
Y, Masuho, Y, Matsumoto, T, Sugano, S, Fujinaga, Y, Minamishima   +4 more
openaire   +2 more sources

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]

, 2019
Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY, Guan, Xin, Kamata, Masakazu, Kranz, Emiko, Lee, YooJin, Liu, Chaoyong, Liu, Yang, Lu, Yunfeng, Martinez-Maza, Otoniel, Qin, Meng, Sun, Guibo, Sun, Xiaobo, Vinters, Harry V, Wang, Lan, Wen, Jing, Widney, Daniel, Wu, Di, Xu, Duo   +17 more
core  

Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma

Advanced Science, EarlyView.
CSPG4 is identified as a high‐value, stemness‐associated target in HPV‐negative HNSCC. By implementing rational biophysical engineering, a humanized and charge‐optimized CAR is developed to overcome tonic signaling‐induced exhaustion. This strategy induces a profound transcriptomic shift toward a rejuvenated, stem‐like memory state, significantly ...
Xiang Xu, Shizhen Qiu, Zhitong Wang, Dan Li, Min Chen, Yinying Chu, Guangfei Li, Yi Fang, Changjiang Li, Fang Shi, Peijie He, Haitao Wu, Haopeng Wang, Jian Chen   +13 more
wiley   +1 more source

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences, 2020
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful.
Joke Verelst, Nick Geukens, Sabiha Eddarkaoui, Dorien Vliegen, Elien De Smidt, Joëlle Rosseels, Vanessa Franssens, Sofie Molenberghs, Cindy Francois, Erik Stoops, Maria Bjerke, Maria Bjerke, Sebastiaan Engelborghs, Sebastiaan Engelborghs, Mohamed Laghmouchi, Sofie Carmans, Luc Buée, Eugeen Vanmechelen, Joris Winderickx, Debby Thomas   +19 more
doaj   +1 more source

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

, 2005
Introduction: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, Elke Jäger, Salah-Eddin Al-Batran, Sibylle Loibl, Akin Atmaca, Christian Cimpoiasu, Antje Neumann, Aklil Abera, Alexander Knuth, Manfred Kaufmann, Dirk Jäger, Alexander B Maurer, Winfried S Wels, MA Olayioye, Y Yarden, J Mendelsohn, DJ Slamon, CL Vogel, I Pastan, W Wels, RJ Kreitman, W Wels, W Wels, IM Harwerth, BH Iglewski, A Keppler-Hafkemeyer, M Schmidt, A Spyridonidis, M Azemar, L Wang, U Altenschmidt, M Maurer-Gebhard, JK Batra, Y Reiter, LH Pai-Scherf, M Azemar, WMA, M Maurer-Gebhard, FDA, J Schumann, M Onda, NJ Olsen, YL Yip, B Gerstmayer, DL Keefe, HS Cho, RJ Kreitman, RJ Kreitman   +49 more
core   +1 more source

PVNCRF Neurons Regulate Migraine‐Like Allodynia by Activating CRFR2 on Spinal Trigeminal Caudalis Glutamatergic Neurons

Advanced Science, EarlyView.
Paraventricular CRF neurons in the hypothalamus project to glutamatergic neurons of the spinal trigeminal caudal nucleus, enhancing neuronal activation and CRFR2 signaling. This pathway increases CRF release and excitatory drive, promoting central sensitization and migraine‐related behaviors. Targeting the PVN–SP5C circuit provides a potential strategy
Jiang Bian, Xiao‐Long Wang, Li Yin, Wei Wei, Xue Li, Yao Ge, Zhao‐Xia Xiang, Na Tian, Li‐Juan Chen, Ming‐Wei Ma, Xia Zhang, Xu Jing, Mei‐Yun Wang, Xu‐Feng Xu   +13 more
wiley   +1 more source